A Phase 4 interventional study of IgPro10 in Immune Thrombocytopenic Purpura, sponsored by CSL Behring. Completed at 17 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-04-08.
Sponsored by CSL Behring (part of CSL Limited) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Romania — 5 open to participants now, 8 under way, 6 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Romania.
Among the 17 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Romania, this one is the 13th largest by enrollment, is the only one that started in 2011, is one of 2 in phase 4, and was the 4th registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →5 of the 17 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Romania are open now. Recruiting first, the newest first:
argenx · Sites in Romania, France, Germany and 7 more countries
Ages 12–17
Kedrion S.p.A. · Sites in Romania, United States, Czechia and 5 more countries
Ages 18–70
argenx · Sites in Romania, United States, Austria and 14 more countries
Ages 18+
Chugai Pharmaceutical · Sites in Romania, United States, Australia and 17 more countries
Ages 18–85
Chugai Pharmaceutical · Sites in Romania, Australia, Austria and 16 more countries
Ages 18–85
A study can be open while its sites in Romania have not opened yet or have stopped. Only those recruiting at a site in Romania →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 11 · Phase 4 2
First in 2005; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 57 is close to the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 99 across the 17 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 17 have an industry lead sponsor. The 9 most frequent:
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
CSL Limited has 3 studies filed under Purpura, Thrombocytopenic, Idiopathic — fewer than ten, so there is no comparison to draw.
3 of the studies in Purpura, Thrombocytopenic, Idiopathic with a site in Romania that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07059000Phase 3Kedrion S.p.A.A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP) | 2026-12 |
| NCT04812925Phase 3argenxA Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia | 2027-10 |
| NCT06371417Chugai PharmaceuticalPhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) | 2027-03-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Romania, from their registry updates:
This tab as a report to print or save as PDF → With an account.
It is known that intravenous immunoglobulins can induce hemolysis, but the mechanism is not known in detail. The primary objective of this study was to investigate the specificity of antigens on red blood cells in patients with chronic immune thrombocytopenic purpura (ITP) who have shown signs of clinically relevant hemolysis following treatment with the intravenous immunoglobin Privigen®. The study was to explore potential mechanisms of hemolysis by analysis of the specificity of the antibodies possibly involved. To distinguish between clinically non-relevant hemolysis and a relevant intravascular hemolysis, an independent adjudication by a committee was performed for each patient with signs of hemolysis determined in the laboratory or in the clinic.
This study was requested as a post-marketing commitment study by the United States Food and Drug Administration (FDA). By September 2014, no case of clinically significant intravascular hemolysis was found, and the FDA agreed to halt the study and analyze all hemolysis-relevant endpoints using FDA criteria for hemolysis in addition to analyses planned in the protocol. The study was not restarted.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: IgPro10
IgPro10 will be administrated by IV infusion either a single dose of 1 g/kg bw on 1 day or 2 doses of 1 g/kg bw on 2 days (2 g/kg bw total dose) dependent on the response to the first treatment.
Also known as: Privigen
Set of Antibodies Most Frequently Bound to Red Blood Cells (RBCs) in Subjects Experiencing Clinically Significant Intravascular Hemolysis
The occurrence of clinically significant intravascular hemolysis was determined by an independent Adjudication Committee. No subject experienced clinically significant intravascular hemolysis; therefore, the primary safety endpoint could not be analyzed.
Time frame: Within 3 days of infusion
Responder Rate
The responder rate is the percentage of subjects who have a platelet response (defined as a platelet count increase at least once to ≥ 50 x 10\^9/L after the first IgPro10 administration).
Time frame: Within 6 days after the first infusion
| Milestone | IgPro10 |
|---|---|
| Started | 57 |
| Completed | 56 |
| Not completed | 1 |
| Withdrew: Physician decision | 1 |
The occurrence of clinically significant intravascular hemolysis was determined by an independent Adjudication Committee. No subject experienced clinically significant intravascular hemolysis; therefore, the primary safety endpoint could not be analyzed.
No measurements were reported for this outcome.
The responder rate is the percentage of subjects who have a platelet response (defined as a platelet count increase at least once to ≥ 50 x 10\^9/L after the first IgPro10 administration).
| percentage of participants | IgPro10 |
|---|---|
| Responder Rate | 74 (61 to 83) |
Collected over For the duration of individual subject participation in the study, up to approximately 35 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IgPro10 | — | 1/57 (1.8%) | 19/57 (33.3%) |
| Event | IgPro10 |
|---|---|
| Immune Thrombocytopenic PurpuraBlood and lymphatic system disorders | 1/57 |
| Event | IgPro10 |
|---|---|
| HeadacheNervous system disorders | 17/57 |
| PyrexiaGeneral disorders | 3/57 |
Subjects treated with Privigen
| Age, Categorical(Participants) | IgPro10 |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 55 |
| >=65 years | 2 |
| Age, Continuous(years) | IgPro10 |
|---|---|
| Mean | 43.5 ± 13.10 |
| Sex: Female, Male(Participants) | IgPro10 |
|---|---|
| Female | 37 |
| Male | 20 |
The record gives a start of Nov 2011, a primary completion of Sep 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: IGPRO10
Purpura, Thrombocytopenic, Idiopathic →